within Pharmacolibrary.Drugs.ATC.B;

model B06AC05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.966666666666668e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0112,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0074199999999999995,
    k12             = 0.235,
    k21             = 0.235
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B06AC05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein and is used as a prophylactic treatment to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years or older. It is approved by regulatory agencies including the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy volunteers and patients with hereditary angioedema (HAE), based on population pharmacokinetic analysis. Subjects included males and females, mainly adults, with subcutaneous administration.</p><h4>References</h4><ol><li><p>Syed, YY (2018). Lanadelumab: First Global Approval. <i>Drugs</i> 78(15) 1633–1637. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0987-2&quot;>10.1007/s40265-018-0987-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30267321/&quot;>https://pubmed.ncbi.nlm.nih.gov/30267321</a></p></li><li><p>Wang, Y, et al., &amp; Martin, P (2020). Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema. <i>Clinical and translational science</i> 13(6) 1208–1216. DOI:<a href=&quot;https://doi.org/10.1111/cts.12806&quot;>10.1111/cts.12806</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32407574/&quot;>https://pubmed.ncbi.nlm.nih.gov/32407574</a></p></li><li><p>Hwang, G, et al., &amp; Craig, T (2019). A review of kallikrein inhibitor lanadelumab in hereditary angioedema. <i>Immunotherapy</i> 11(11) 937–944. DOI:<a href=&quot;https://doi.org/10.2217/imt-2018-0197&quot;>10.2217/imt-2018-0197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31234673/&quot;>https://pubmed.ncbi.nlm.nih.gov/31234673</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B06AC05;
